1. Role: Director. Scope: Department. Date: 2019.
Grant H. Skrepnek, Ph.D., R.Ph.
Professor
Pharmacy Clinical & Admin Sci
Phone (405) 271-6878 x47105
Fax (4050 271-6430
Office CPB 214
Email grant-skrepnek@ouhsc.edu
Summary
Grant H. Skrepnek, Ph.D., M.Sc., R.Ph. is President’s Associates Presidential Professor at The University of Oklahoma Health Sciences and serves as Director of Academic Research within Pharmacy Management Consultants, a unit of OU’s College of Pharmacy that serves Oklahoma’s State Medicaid program. He has published over 100 scientific articles and has received over $30 million in funding as Principal Investigator from numerous federal, industry, and foundation sponsors including PCORI, CMS, AHRQ, NIH/OSCTR, and the CDC to conduct service and research across in the areas of health economics and finance, treatment outcomes, patient safety and error reduction, and healthcare policy. His research has appeared nationally and internationally, highlighted by The White House, AHRQ, Fox News, ABC News, U.S. News & World Report, the WHO, Business Wire, and the CBO.
Dr. Skrepnek teaches across OU’s Colleges of Business, Pharmacy, Medicine, and Public Health, chairs the Pharmacy Administration Ph.D. program within the Graduate College, co-chairs the Faculty Appeals Committee, and chairs both the Health Sciences’ Research and Information Technology Research Councils. He served on the National Steering Committee for the NCI’s Community Oncology Research Program (NCORP), NRG Oncology Cancer Care and Delivery Research Committee (CCDR), is on the Editorial Board of Healthcare and the Journal of Commercial Biotechnology, and served as an Editor for Current Medical Research and Opinion, which was a recipient of the Queen’s Award for Enterprise in International Trade. In his role at OU College of Pharmacy as the Director of Academic Research, Dr. Skrepnek provides oversight for analytic, operational, consultant, and educational services to Oklahoma’s Medicaid program in administering pharmacy benefits and prior authorizations with over 50 clinicians, students, and staff to achieve federal regulatory compliance for drug utilization reviews. Further, he conducts analytics for Oklahoma Medicaid’s value-based agreements via sponsorship and oversight from CMS. He frequently collaborates with numerous organizations and firms relating to pharmacoeconomics, research and development, asset valuation, mergers and acquisitions, strategic management, and executive training.
Dr. Skrepnek received his Pharmacy, M.Sc., and Ph.D. degrees at the University of Texas at Austin with an emphasis in healthcare finance, economics, advanced statistics and econometrics, and strategic management. Prior to arriving at OU, he was faculty at The University of Arizona College of Pharmacy, with research appointments in the Arizona Cancer Center and within institutes in Arizona’s departments of Emergency Medicine and Surgery. He is a member of Phi Kappa Phi Honor Society, Rho Chi Pharmacy Honor Society, Phi Lambda Sigma Leadership Society, and Kappa Psi Pharmaceutical Fraternity.
Research
Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Publications & Presentations
- 11. Rathbun C, Lewis M M, Yuet W C, Woo S, Miller J L, Skrepnek G H. The Medication Possession Ratio as a Predictor of Longitudinal HIV-1 Viral Suppression. The Annals of pharmacotherapy. 2023; 57 : 1264-1272
12. Boylan P, Skrepnek G, Neely S. Medication therapy problems assessment within medication history objective structured clinical examinations using standardized patients versus peer actors. Journal of the American College of Clinical Pharmacy. 2023; 6 : 354-362
13. Nguyen M M, Dickson M C, Skrepnek G H. Medicaid Value-Based Contract (VBC) in autoimmune diseases involving tumor necrosis factor. Oklahoma Health Care Authority. 2022
14. Nguyen M, Dickson M C, Skrepnek G H. Medicaid Value-Based Contract (VBC) in partial-onset seizure disorder. Oklahoma Health Care Authority. 2022
15. Dickson M C, Nguyen M M, Skrepnek G H. Medicaid Value-Based Contract (VBC) in the prevention of migraine. Oklahoma Health Care Authority. 2022
Grants
- 1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2025.
2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2025.
3. HIV Adherence Services. Start Date: 2022. End Date: 2023.
4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.
5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.
Awards and Honors
- 1. Presidents Associates. Presidential Professor. Date: 2024.
2. Academy of Managed Care Pharmacy Nexus 2022, National Harbor, MD, Oct. 11-14, 2022. Top Conference Poster (Student, Matthew C. Dickson). Date: 2022.
3. Academy of Managed Care Pharmacy. Bronze Recognition. Date: 2015.
4. International Symposium of the Diabetic Foot. Top Conference Podium. Date: 2015.
Education
no results
Administrative Assignments
2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.